References
- GBD 2015 Chronic Respiratory Disease CollaboratorsGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
- MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD2018 Available from: http://www.goldcopd.orgAccessed May 5, 2018
- VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
- DotyASchroederJVangKDrug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliabilityAAPS PharmSciTech201819283784429019170
- TaylorGWarrenSDwivediSGamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technologyEur J Pharm Sci201811145045729055732
- AstraZeneca PharmaceuticalsLPBevespi Aerosphere™ Prescribing Information2017 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed May 5, 2018
- HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
- MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
- ReisnerCFabbriLMKerwinEMA randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseRespir Res2017181828061907
- TashkinDPMartinezFJRodriguez-RoisinRA multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPDRespir Med2016120162427817811
- CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
- BauerPRöhmelJMaurerWHothornLTesting strategies in multi-dose experiments including active controlStat Med19981718213321469789919
- MurraySUsing weighted Kaplan-Meier statistics in nonparametric comparisons of paired censored survival outcomesBiometrics200157236136811414557
- AlaghaKPalotASofalviTLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesTher Adv Chronic Dis201452859824587893
- SharafkhanehAMajidHGrossNJSafety and tolerability of inhalational anticholinergics in COPDDrug Healthc Patient Saf20135495523526112
- TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
- BattistiWPWagerEBaltzerLGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067